article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

article thumbnail

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

The Pharma Data

On February 7, 2020 the NYSE American notified the Company that it accepted the Company’s plan to regain compliance before November 25, 2020 , the end of the compliance plan period. This date has now been extended to May 25, 2021. About Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hyman, Phelps & McNamara, P.C. (HP&M) is Pleased to Announce the Addition of Sara M. Keup as the new State Licensing Regulatory Expert for the Firm’s Licensing Practice

FDA Law Blog: Biosimilars

HP&M has been helping clients navigate the challenges of state licensing regulations for drugs, biologics, medical devices, OTCs, 503B outsourcing facilities, 503A pharmacies, foods, dietary supplements, cannabis, and wholesalers/distributors for many years.

article thumbnail

5 Major Benefits of Azure Integration Services Over MuleSoft

Perficient: Drug Development

Additionally, AIS often incurs significantly lower licensing and maintenance costs, making it an attractive option for organizations looking to optimize their IT expenditure. Enhanced Security and Compliance Security and compliance are top priorities for any integration platform.

article thumbnail

DFS500 Amendments: What You Need to Know

Perficient: Drug Development

These DFS500 amendments signal a crucial shift in the regulatory landscape, emphasizing the imperative for robust governance, risk management, and compliance frameworks across the financial industry. Impacted institutions are subject to significant fines relative to the level of non-compliance identified by the regulators.

article thumbnail

NYSDFS Part 500 Cyber Amendments Finalized: What You Need to Know

Perficient: Drug Development

The NYSDFS Part 500 amendments signal a crucial shift in the financial services regulatory landscape and underscore the importance of robust governance, risk management, and compliance frameworks. Impacted institutions are subject to significant fines relative to the level of non-compliance identified by the regulators.

article thumbnail

Deep Dive into IBM Sterling Certified Containers and Cloud Solutions

Perficient: Drug Development

The container technology also supports varying levels of technical acumen, business continuity, security, and compliance. This distribution utilizes licensed API keys, streamlining the process for customers to conveniently retrieve and access these containers in their local registries or incorporate them seamlessly into their CI/CD pipelines.